• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Amylyx Pharmaceuticals Inc. (Amendment)

    8/17/23 5:15:29 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMLX alert in real time by email
    SC 13D/A 1 d528863dsc13da.htm SC 13D/A SC 13D/A

    CUSIP No. 03237H101

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)*

     

     

    Amylyx Pharmaceuticals, Inc.

    (Name of Issuer)

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    03237H101

    (CUSIP Number)

    Morningside Venture Investments Limited

    C/O THC Management Services S.A.M.,

    2nd Floor,

    Le Prince De Galles

    3-5 Avenue Des Citronniers

    Monaco, MC 98000

    011-377-97-97-47-37

    with a copy to:

    Morningside Technology Advisory, LLC

    Attn: Daniel White, Esq.

    1188 Centre Street

    Newton Centre, MA 02459

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    August 15, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes)

     

     

     

     


    CUSIP No. 03237H101

     

      (1)   

    Names of Reporting Persons

     

    Morningside Venture Investments Limited

      (2)  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)  ☒        (b)  ☐

     

      (3)  

    SEC Use Only

     

      (4)  

    Source of Funds (See Instructions)

     

    WC

      (5)  

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

    ☐

      (6)  

    Citizenship or Place of Organization

     

    British Virgin Islands

    Number of

    Shares

    Beneficially  

    Owned by

    Each

    Reporting

    Person

    With:

     

         (7)    

    Sole Voting Power

     

    0

         (8)   

    Shared Voting Power

     

    4,618,846

         (9)   

    Sole Dispositive Power

     

    0

       (10)   

    Shared Dispositive Power

     

    4,618,846

    (11)  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    4,618,846

    (12)  

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

    ☐

    (13)  

    Percent of Class Represented by Amount in Row (11)

     

    6.86% (1)

    (14)   

    Type of Reporting Person (See Instructions)

     

    CO

     

    (1)

    Based on 67,377,743 shares of Common Stock outstanding as of August 7, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on August 10, 2023.


    CUSIP No. 03237H101

     

      (1)   

    Names of Reporting Persons

     

    MVIL, LLC

      (2)  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)  ☒        (b)  ☐

     

      (3)  

    SEC Use Only

     

      (4)  

    Source of Funds (See Instructions)

     

    WC

      (5)  

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

    ☐

      (6)  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially  

    Owned by

    Each

    Reporting

    Person

    With:

     

         (7)    

    Sole Voting Power

     

    0

         (8)   

    Shared Voting Power

     

    1,621,544

         (9)   

    Sole Dispositive Power

     

    0

       (10)   

    Shared Dispositive Power

     

    1,621,544

    (11)  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,621,544

    (12)  

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

    ☐

    (13)  

    Percent of Class Represented by Amount in Row (11)

     

    2.41% (1)

    (14)   

    Type of Reporting Person (See Instructions)

     

    CO

     

    (1)

    Based on 67,377,743 shares of Common Stock outstanding as of August 7, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 10, 2023.


    CUSIP No. 03237H101

     

      (1)   

    Names of Reporting Persons

     

    Frances Anne Elizabeth Richard

      (2)  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)  ☒        (b)  ☐

     

      (3)  

    SEC Use Only

     

      (4)  

    Source of Funds (See Instructions)

     

    AF

      (5)  

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

    ☐

      (6)  

    Citizenship or Place of Organization

     

    United Kingdom

    Number of

    Shares

    Beneficially  

    Owned by

    Each

    Reporting

    Person

    With:

     

         (7)    

    Sole Voting Power

     

    0

         (8)   

    Shared Voting Power

     

    4,618,846

         (9)   

    Sole Dispositive Power

     

    0

       (10)   

    Shared Dispositive Power

     

    4,618,846

    (11)  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    4,618,846

    (12)  

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

    ☐

    (13)  

    Percent of Class Represented by Amount in Row (11)

     

    6.86% (1)

    (14)   

    Type of Reporting Person (See Instructions)

     

    IN

     

    (1)

    Based on 67,377,743 shares of Common Stock outstanding as of August 7, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 10, 2023.


    CUSIP No. 03237H101

     

      (1)   

    Names of Reporting Persons

     

    Jill Marie Franklin

      (2)  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)  ☒        (b)  ☐

     

      (3)  

    SEC Use Only

     

      (4)  

    Source of Funds (See Instructions)

     

    AF

      (5)  

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

    ☐

      (6)  

    Citizenship or Place of Organization

     

    United Kingdom

    Number of

    Shares

    Beneficially  

    Owned by

    Each

    Reporting

    Person

    With:

     

         (7)    

    Sole Voting Power

     

    0

         (8)   

    Shared Voting Power

     

    4,618,846

         (9)   

    Sole Dispositive Power

     

    0

       (10)   

    Shared Dispositive Power

     

    4,618,846

    (11)  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    4,618,846

    (12)  

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

    ☐

    (13)  

    Percent of Class Represented by Amount in Row (11)

     

    6.86% (1)

    (14)   

    Type of Reporting Person (See Instructions)

     

    IN

     

    (1)

    Based on 67,377,743 shares of Common Stock outstanding as of August 7, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 10, 2023.


    CUSIP No. 03237H101

     

      (1)   

    Names of Reporting Persons

     

    Peter Stuart Allenby Edwards

      (2)  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)  ☒        (b)  ☐

     

      (3)  

    SEC Use Only

     

      (4)  

    Source of Funds (See Instructions)

     

    AF

      (5)  

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

    ☐

      (6)  

    Citizenship or Place of Organization

     

    United Kingdom

    Number of

    Shares

    Beneficially  

    Owned by

    Each

    Reporting

    Person

    With:

     

         (7)    

    Sole Voting Power

     

    0

         (8)   

    Shared Voting Power

     

    4,618,846

         (9)   

    Sole Dispositive Power

     

    0

       (10)   

    Shared Dispositive Power

     

    4,618,846

    (11)  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    4,618,846

    (12)  

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

    ☐

    (13)  

    Percent of Class Represented by Amount in Row (11)

     

    6.86% (1)

    (14)   

    Type of Reporting Person (See Instructions)

     

    IN

     

    (1)

    Based on 67,377,743 shares of Common Stock outstanding as of August 7, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 10, 2023.


    CUSIP No. 03237H101

     

      (1)   

    Names of Reporting Persons

     

    Cheung Ka Ho

      (2)  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)  ☒        (b)  ☐

     

      (3)  

    SEC Use Only

     

      (4)  

    Source of Funds (See Instructions)

     

    AF

      (5)  

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

    ☐

      (6)  

    Citizenship or Place of Organization

     

    Hong Kong

    Number of

    Shares

    Beneficially  

    Owned by

    Each

    Reporting

    Person

    With:

     

         (7)    

    Sole Voting Power

     

    0

         (8)   

    Shared Voting Power

     

    4,618,846

         (9)   

    Sole Dispositive Power

     

    0

       (10)   

    Shared Dispositive Power

     

    4,618,846

    (11)  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    4,618,846

    (12)  

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

    ☐

    (13)  

    Percent of Class Represented by Amount in Row (11)

     

    6.86% (1)

    (14)   

    Type of Reporting Person (See Instructions)

     

    IN

     

    (1)

    Based on 67,377,743 shares of Common Stock outstanding as of August 7, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 10, 2023.


    CUSIP No. 03237H101

     

      (1)   

    Names of Reporting Persons

     

    Cheng Yee Wing Betty

      (2)  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)  ☒        (b)  ☐

     

      (3)  

    SEC Use Only

     

      (4)  

    Source of Funds (See Instructions)

     

    AF

      (5)  

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

    ☐

      (6)  

    Citizenship or Place of Organization

     

    Hong Kong

    Number of

    Shares

    Beneficially  

    Owned by

    Each

    Reporting

    Person

    With:

     

         (7)    

    Sole Voting Power

     

    0

         (8)   

    Shared Voting Power

     

    1,621,544

         (9)   

    Sole Dispositive Power

     

    0

       (10)   

    Shared Dispositive Power

     

    1,621,544

    (11)  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,621,544

    (12)  

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

    ☐

    (13)  

    Percent of Class Represented by Amount in Row (11)

     

    2.41% (1)

    (14)   

    Type of Reporting Person (See Instructions)

     

    IN

     

    (1)

    Based on 67,377,743 shares of Common Stock outstanding as of August 7, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 10, 2023.


    CUSIP No. 03237H101

     

      (1)   

    Names of Reporting Persons

     

    Wong See Wai

      (2)  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)  ☒        (b)  ☐

     

      (3)  

    SEC Use Only

     

      (4)  

    Source of Funds (See Instructions)

     

    AF

      (5)  

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

    ☐

      (6)  

    Citizenship or Place of Organization

     

    Hong Kong

    Number of

    Shares

    Beneficially  

    Owned by

    Each

    Reporting

    Person

    With:

     

         (7)    

    Sole Voting Power

     

    0

         (8)   

    Shared Voting Power

     

    1,621,544

         (9)   

    Sole Dispositive Power

     

    0

       (10)   

    Shared Dispositive Power

     

    1,621,544

    (11)  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,621,544

    (12)  

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

    ☐

    (13)  

    Percent of Class Represented by Amount in Row (11)

     

    2.41% (1)

    (14)   

    Type of Reporting Person (See Instructions)

     

    IN

     

    (1)

    Based on 67,377,743 shares of Common Stock outstanding as of August 7, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 10, 2023.


    CUSIP No. 03237H101

     

    Item 1. Security and Issuer.

    This Amendment No. 3 (“Amendment No. 3”) to Schedule 13D amends and supplements the statement on Schedule 13D originally filed on January 25, 2022 (the “Initial Statement”), Amendment No. 1 to the Initial Statement filed on September 30, 2022 and Amendment No. 2 to the Initial Statement filed on April 3, 2023. This Amendment No. 3 on Schedule 13D relates to the Reporting Persons’ (as defined in Item 2 below) beneficial ownership interest in the common stock, par value $0.0001 per share (the “Common Stock”), of Amylyx Pharmaceuticals, Inc., a Delaware corporation (the “Issuer”). The address of the principal executive office of the Issuer is 43 Thorndike St., Cambridge, Massachusetts 02141. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.

    Item 3. Source and Amount of Funds or Other Consideration.

    Item 3 of the Initial Statement is hereby amended and supplemented to add the following:

    On August 15, 2023, MVIL donated an aggregate of 2,000,000 shares of Common Stock to a 501(c)(3) organization.

    On August 16, 2023, MVIL made an open market sale for an aggregate of 2,000,000 shares of Common Stock at a price per share of $19.62.

    Item 5. Interest in Securities of the Issuer.

    Item 5 of the Initial Statement is hereby amended as the following:

     

      (1)

    The aggregate percentage of Common Stock reported beneficially owned by each person named herein is determined in accordance with SEC rules and is based on 67,377,743 shares of Common Stock outstanding as of August 7, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 10, 2023. The applicable SEC rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities.

     

    A.

    Morningside Venture Investments Limited

     

      (a)

    As of the date hereof, MVIL beneficially owns 4,618,846 shares of Common Stock, representing a beneficial ownership of approximately 6.86% of the Common Stock. MVIL directly holds 2,997,302 shares of Common Stock and MVIL LLC, its wholly owned subsidiary, holds 1,621,544 shares of Common Stock.

     

    (b)

       1. Sole power to vote or direct vote:      -0-  
       2. Shared power to vote or direct vote:      4,618,846  
       3. Sole power to dispose or direct the disposition:      -0-  
       4. Shared power to dispose or direct the disposition:      4,618,846  

     

    B.

    MVIL, LLC

     

      (a)

    As of the date hereof, MVIL LLC beneficially owns 1,621,544 shares of Common Stock, representing a beneficial ownership of approximately 2.41% of the Common Stock.

     

    (b)

       1. Sole power to vote or direct vote:      -0-  
       2. Shared power to vote or direct vote:      1,621,544  
       3. Sole power to dispose or direct the disposition:      -0-  
       4. Shared power to dispose or direct the disposition:      1,621,544  


    CUSIP No. 03237H101

     

    C.

    Frances Anne Elizabeth Richard

     

      (a)

    As of the date hereof, Ms. Richard beneficially owns 4,618,846 shares of Common Stock, representing a beneficial ownership of approximately 6.86% of the Common Stock. Ms. Richard disclaims any personal beneficial ownership of such Common Stock.

     

    (b)

       1. Sole power to vote or direct vote:      -0-  
       2. Shared power to vote or direct vote:      4,618,846  
       3. Sole power to dispose or direct the disposition:      -0-  
       4. Shared power to dispose or direct the disposition:      4,618,846  

     

    D.

    Jill Marie Franklin

     

      (a)

    As of the date hereof, Ms. Franklin beneficially owns 4,618,846 shares of Common Stock, representing a beneficial ownership of approximately 6.86% of the Common Stock. Ms. Franklin disclaims any personal beneficial ownership of such Common Stock.

     

    (b)

       1. Sole power to vote or direct vote:      -0-  
       2. Shared power to vote or direct vote:      4,618,846  
       3. Sole power to dispose or direct the disposition:      -0-  
       4. Shared power to dispose or direct the disposition:      4,618,846  

     

    E.

    Peter Stuart Allenby Edwards

     

      (a)

    As of the date hereof, Mr. Edwards beneficially owns 4,618,846 shares of Common Stock, representing a beneficial ownership of approximately 6.86% of the Common Stock. Mr. Edwards disclaims any personal beneficial ownership of such Common Stock.

     

    (b)

       1. Sole power to vote or direct vote:      -0-  
       2. Shared power to vote or direct vote:      4,618,846  
       3. Sole power to dispose or direct the disposition:      -0-  
       4. Shared power to dispose or direct the disposition:      4,618,846  

     

    F.

    Cheung Ka Ho

     

      (a)

    As of the date hereof, Mr. Cheung beneficially owns 4,618,846 shares of Common Stock, representing a beneficial ownership of approximately 6.86% of the Common Stock. Mr. Cheung disclaims any personal beneficial ownership of such Common Stock.

     

    (b)

       1. Sole power to vote or direct vote:      -0-  
       2. Shared power to vote or direct vote:      4,618,846  
       3. Sole power to dispose or direct the disposition:      -0-  
       4. Shared power to dispose or direct the disposition:      4,618,846  

     

    G.

    Cheng Yee Wing Betty

     

      (a)

    As of the date hereof, Ms. Cheng beneficially owns 1,621,544 shares of Common Stock, representing a beneficial ownership of approximately 2.41% of the Common Stock. Ms. Cheng disclaims any personal beneficial ownership of such Common Stock.

     

    (b)

       1. Sole power to vote or direct vote:      -0-  
       2. Shared power to vote or direct vote:      1,621,544  
       3. Sole power to dispose or direct the disposition:      -0-  
       4. Shared power to dispose or direct the disposition:      1,621,544  

     

    H.

    Wong See Wai

     

      (a)

    As of the date hereof, Mr. Wong beneficially owns 1,621,544 shares of Common Stock, representing a beneficial ownership of approximately 2.41% of the Common Stock. Mr. Wong disclaims any personal beneficial ownership of such Common Stock.

     

    (b)

       1. Sole power to vote or direct vote:      -0-  
       2. Shared power to vote or direct vote:      1,621,544  
      

    3. Sole power to dispose or direct the disposition:

         -0-  
      

    4. Shared power to dispose or direct the disposition:

         1,621,544  


    CUSIP No. 03237H101

     

      (c)

    See Item 3.

     

      (d)

    Not applicable.

     

      (e)

    Not applicable.

    Item 7. Material to be Filed as Exhibits.

    The following documents are filed as Exhibits to this statement.

     

    Exhibit

    Number

      

    Exhibit Description

    99.1    Joint Filing Agreement


    CUSIP No. 03237H101

     

    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, we certify that the information set forth in this statement is true, complete and correct. We also hereby agree to file this statement jointly pursuant to the Agreement listed on Exhibit 99.1 hereto.

    Dated: August 17, 2023

    For and on behalf of

     

    MORNINGSIDE VENTURE INVESTMENTS LIMITED
    By:  

    /s/ Frances Anne Elizabeth Richard

      Frances Anne Elizabeth Richard, Director
    For and on behalf of
    MVIL, LLC
    By:  

    /s/ Cheng Yee Wing Betty

      Cheng Yee Wing, Manager

    /s/ Frances Anne Elizabeth Richard

    Frances Anne Elizabeth Richard

    /s/ Jill Marie Franklin

    Jill Marie Franklin

    /s/ Peter Stuart Allenby Edwards

    Peter Stuart Allenby Edwards

    /s/ Cheung Ka Ho

    Cheung Ka Ho

    /s/ Cheng Yee Wing Betty

    Cheng Yee Wing Betty

    /s/ Wong See Wai

    Wong See Wai

     

    Get the next $AMLX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMLX

    DatePrice TargetRatingAnalyst
    7/10/2025$10.00Buy
    Goldman
    6/24/2025$17.00Buy
    Guggenheim
    6/17/2025$12.00Buy
    Citigroup
    5/30/2025Buy
    TD Cowen
    4/7/2025$7.00Neutral → Outperform
    Mizuho
    11/18/2024$3.00 → $11.00Neutral → Outperform
    Robert W. Baird
    10/23/2024$4.20 → $10.00Neutral → Buy
    BofA Securities
    3/18/2024$32.00 → $4.00Buy → Neutral
    Mizuho
    More analyst ratings

    $AMLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman resumed coverage on Amylyx Pharmaceuticals with a new price target

    Goldman resumed coverage of Amylyx Pharmaceuticals with a rating of Buy and set a new price target of $10.00

    7/10/25 8:47:27 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Amylyx Pharmaceuticals with a new price target

    Guggenheim initiated coverage of Amylyx Pharmaceuticals with a rating of Buy and set a new price target of $17.00

    6/24/25 7:57:48 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on Amylyx Pharmaceuticals with a new price target

    Citigroup initiated coverage of Amylyx Pharmaceuticals with a rating of Buy and set a new price target of $12.00

    6/17/25 7:48:19 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Co-Chief Executive Officer Cohen Joshua B sold $227,593 worth of shares (15,500 units at $14.68), decreasing direct ownership by 0.46% to 3,363,965 units (SEC Form 4)

    4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)

    2/4/26 4:05:16 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Frates James M sold $52,097 worth of shares (3,557 units at $14.65), decreasing direct ownership by 2% to 173,547 units (SEC Form 4)

    4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)

    2/4/26 4:05:19 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Legal Officer Mazzariello Gina sold $50,516 worth of shares (3,448 units at $14.65), decreasing direct ownership by 2% to 144,693 units (SEC Form 4)

    4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)

    2/4/26 4:05:11 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Firestone Karen bought $100,845 worth of shares (8,100 units at $12.45), increasing direct ownership by 15% to 63,100 units (SEC Form 4)

    4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)

    12/23/25 8:48:33 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Zeiher Bernhardt G bought $37,005 worth of shares (10,000 units at $3.70) (SEC Form 4)

    4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)

    3/24/25 4:15:37 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Frates James M bought $101,368 worth of shares (40,000 units at $2.53), increasing direct ownership by 21% to 233,464 units (SEC Form 4)

    4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)

    9/16/24 5:30:37 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMLX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Amylyx Pharmaceuticals Inc.

    SCHEDULE 13G/A - Amylyx Pharmaceuticals, Inc. (0001658551) (Subject)

    2/5/26 1:16:32 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Amylyx Pharmaceuticals Inc.

    144 - Amylyx Pharmaceuticals, Inc. (0001658551) (Subject)

    2/2/26 4:10:02 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Amylyx Pharmaceuticals Inc.

    144 - Amylyx Pharmaceuticals, Inc. (0001658551) (Subject)

    2/2/26 4:10:01 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra A/S

    AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high solubility, and a favorable pharmacokinetic profile consistent with a long-acting peptide IND-enabling studies expected to initiate in 2026 with an IND targeted for 2027, pending successful completion of IND-enabling studies Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced the selection of AMX0318, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist, as a development candidate for post-bariatric hypoglycemia (PBH) and other rare disease

    1/8/26 7:00:00 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial

    - AMX0114 was generally well-tolerated, with no treatment-related serious adverse events - Amylyx will proceed with opening enrollment of second cohort - Data are being presented at the 36th International Symposium on ALS/MND Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced the presentation of early safety and tolerability data from its Phase 1 LUMINA trial of AMX0114 and results from ongoing work characterizing biomarkers of AMX0114 target engagement at the 36th International Symposium on ALS/MND (MNDA) held from December 5-7 in San Diego, California. AMX0114 was generally well-tolerated in LUMINA trial participants enrolled in cohort 1 (n=12), with

    12/5/25 9:00:00 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences

    Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that management will present at the following upcoming conferences, which are being conducted in-person: Guggenheim 2nd Annual Healthcare Innovation Conference: Fireside chat on Monday, November 10, 2025, at 4:30pm ET in Boston, Massachusetts 8th Annual Evercore Healthcare Conference: Fireside Chat on Tuesday, December 2, 2025, at 8:20am ET in Coral Gables, Florida Citi's 2025 Global Healthcare Conference: Fireside Chat on Wednesday, December 3, 2025, at 4:00pm ET in Miami, Florida A live webcast of each fireside chat can be accessed under "Events and Presentations" in the Investor section of

    11/3/25 9:00:00 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMLX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    September 29, 2022 - FDA Approves New Treatment Option for Patients with ALS

    For Immediate Release: September 29, 2022 The U.S. Food and Drug Administration today approved Relyvrio (sodium phenylbutyrate/taurursodiol) to treat patients with amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig’s disease.  “This approval provides another important treatment option for ALS, a life-threatening disease that currently has no cure,” said Billy Dunn, M.D., director of the Off

    9/29/22 5:02:14 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    September 2, 2022 - FDA Roundup: September 2, 2022

    For Immediate Release: September 02, 2022 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:   On Thursday, the FDA published the FDA Voices: “Using A Whole-Of-Governments Approach to Combating Illicit Health Products,” by Cathy Hermsen, Assistant Commissioner for Criminal Investigations and Ritu Nalubola, Director of the FDA’s Europe Office. Crimi

    9/2/22 1:46:13 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMLX
    Financials

    Live finance-specific insights

    View All

    Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial

    - AMX0114 was generally well-tolerated, with no treatment-related serious adverse events - Amylyx will proceed with opening enrollment of second cohort - Data are being presented at the 36th International Symposium on ALS/MND Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced the presentation of early safety and tolerability data from its Phase 1 LUMINA trial of AMX0114 and results from ongoing work characterizing biomarkers of AMX0114 target engagement at the 36th International Symposium on ALS/MND (MNDA) held from December 5-7 in San Diego, California. AMX0114 was generally well-tolerated in LUMINA trial participants enrolled in cohort 1 (n=12), with

    12/5/25 9:00:00 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

    Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") will report its third quarter 2025 financial results on Thursday, November 6, 2025. Amylyx' senior management team will host a conference call and audio webcast at 8:00 a.m. ET to discuss the financial results and other company updates. To access the conference call, please dial +1 (888) 880-3330 (U.S. & Canada) or +1 (646) 357-8766 (international) at least 10 minutes prior to the start time and ask to be joined into the Amylyx Pharmaceuticals call. A live audio webcast of the call will be available under "Events and Presentations" in the Investor section of the Company's website, https://investors.amylyx.com/events-pr

    10/30/25 9:00:00 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results

    Completion of recruitment for pivotal Phase 3 LUCIDITY trial of avexitide in PBH expected in 2025, with topline data anticipated in first half of 2026 Cash, cash equivalents, and marketable securities of $180.8 million as of June 30, 2025; cash runway expected through the end of 2026 Management to host conference call and webcast today at 8:00 a.m. Eastern Time   Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today reported financial and business results for the second quarter ended June 30, 2025. "As we look ahead to the second half of the year and into 2026, we remain encouraged by the strength of our pipeline and the continued momentum towards our cl

    8/7/25 7:00:00 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMLX
    Leadership Updates

    Live Leadership Updates

    View All

    Amylyx Pharmaceuticals, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; April 9, 2024 deadline

    Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, April 08, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) investors that a lawsuit was filed on behalf of investors that purchased Amylyx securities between November 11, 2022 and November 8, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursui

    4/8/24 6:24:09 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amylyx Pharmaceuticals Appoints Camille L. Bedrosian, MD, as Chief Medical Officer

    - Dr. Bedrosian brings to Amylyx nearly 30 years of leadership in clinical research, development, and advancing pipeline programs into commercialized global products including as CMO at Ultragenyx, Alexion, and ARIAD Pharmaceuticals Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced the appointment of Camille L. Bedrosian, MD, as Chief Medical Officer ("CMO"). In this role, Dr. Bedrosian will lead global functions in medical affairs, regulatory, safety and pharmacovigilance, biometrics, clinical development, and clinical operations. Dr. Bedrosian brings nearly 30 years of experience addressing unmet medical needs for people with rare and serious disease

    11/28/23 7:00:00 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amylyx Pharmaceuticals Receives CHMP Negative Opinion on its Conditional Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union

    Amylyx will seek re-examination of its Conditional Marketing Authorisation Application Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the application for conditional marketing authorisation of AMX0035 (sodium phenylbutyrate and ursodoxicoltaurine [also known as taurursodiol]), under the trade name ALBRIOZA®, for the treatment of adults with amyotrophic lateral sclerosis (ALS) in the European Union (EU). Today's update follows the Company's May 2023 announcement that the CHMP was trending toward a negative opinion.

    6/23/23 8:14:00 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Amylyx Pharmaceuticals Inc.

    SC 13G/A - Amylyx Pharmaceuticals, Inc. (0001658551) (Subject)

    11/12/24 1:22:53 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Amylyx Pharmaceuticals Inc.

    SC 13G - Amylyx Pharmaceuticals, Inc. (0001658551) (Subject)

    11/4/24 10:56:42 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Amylyx Pharmaceuticals Inc.

    SC 13G - Amylyx Pharmaceuticals, Inc. (0001658551) (Subject)

    10/25/24 5:38:25 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care